Neurocrine Biosciences Inc(NBIX)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

NBIX iron condor setups NBIX expected move NBIX IV rank history

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$167.21
52-Week Range
$122.14 – $169.57
YTD
+18.93%
IV Rank (30D)
13.55
Straddle Price
$9.60
P/C Vol Ratio
0.47
Market Cap
$16.5B
Fair Value
+20.9% vs price
Confidence: 72% Alpha Score: 0.27

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.50%
Beta vs SPY1.00
Cost of Equity (CAPM)10.00% (VRP-adj)
WACC9.72%
Volatility Risk Premium+21.9pp (IV − HV30), ERP adj +50bps
Effective Tax Rate28.7%
Rev. Growth (YoY, DCF input)+18.5%
DCF Horizon15 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.8B
Return on Equity (TTM)19.6%
Book / Price20.3%
Gross Margin (TTM)98.2%
FCF Margin (TTM)26.8%
Debt / Equity0.00
Quality Score6/6 — compounder (15y DCF)
Market-Implied Growth+7.3% (reverse-DCF on current price)
SMA 50$150.26 (Market Anchor value)
SMA 20 / Bollinger Mid$161.25
Bollinger Width / SMA205.2% (drives anchor stability)
Net Debt$-0.3B
Market Cap$17B
Peers used for multiples: ALNY, AMGN, BIIB, GILD, REGN, RPRX, UTHR, VRTX
Blended Fair Value
$203.75
Current Price
$168.52
Deviation
+20.9%
Forward-Return Rank LONG gates ✓
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -0.2% ⚠ +1.39 +0.82 73.4% —
42d -1.1% ⚠ +1.54 +0.90 71.1% —
63d -0.5% ⚠ +1.38 +0.82 63.9% —
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. ⚠ flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF $359.58 23%
DDM (Gordon) n/a 0%
Peer P/E $162.38 10% median 22.7× · 8 peers
Peer EV/EBITDA $139.26 10% median 15.3× · 8 peers
Peer P/B $169.62 2% median 5.1× · 8 peers
Peer P/S $209.89 7% median 6.3× · 8 peers
Market Anchor (SMA50) $150.26 47% stability 100% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-26 · updated 2026-06-26 20:59:30.580000
Info
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
Exchange
XNAS
Market Cap
$16.5B

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, includ…

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan +9.59% 23
Feb -2.41% 23
Mar +1.63% 23
Apr +0.47% 23
May +2.13% 23
Jun +1.07% 23
Jul +0.75% 22
Aug +1.83% 22
Sep -3.08% 23
Oct +1.33% 23
Nov +1.01% 23
Dec +1.02% 23
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $161.86
SMA 50: $151.00
SMA 200: $141.85
Current: $168.52
EMA 12: $162.63
EMA 26: $159.29
MACD: 3.3342 | Signal: -0.0761
BULLISH
ADX (14): 34.17
TREND
+DI: 25.20
−DI: 9.94
Momentum Oscillators
RSI (14): 64.14
NEUTRAL
Stoch %K: 77.04
Stoch %D: 64.58
Williams %R: -7.29
Volume & Volatility
BB Upper: $168.94
BB Lower: $154.79
NEUTRAL
OBV: 39,925,630
Vol SMA 20: 1,269,666
Vol ROC: 155.32%
ATR: $4.91
True Range: $6.44
HV 20: 37.3%
HV 30: 31.6%
HV 60: 34.1%
Data Summary
Data Points: 500
Last Updated: 2026-06-26T21:15:12.285000
Date Range: 2024-06-28T00:00:00 – 2026-06-26T00:00:00
AI Analysis

LLM Stock Analysis Report: NBIX

Executive Summary Overall Assessment: NEUTRAL (Confidence Level: 6/10) Key Drivers and Primary Risks: * Strong technical signals, including MACD's bullish crossover and RSI's neutral reading * Positive news sentiment from recent headlines, particularly those highlighting partnerships and operational highlights * Low volatility and beta indicate a defensive stock with moderate risk

Technical Analysis Trend Direction: Short-term - Uptrend; Medium-term - Consolidation; Long-term - Uptrend Support/Resistance Levels: * SMA 20: $161.25 (support) * Upper Bollinger Band: $168.01 (resistance)

Momentum Signals: * RSI: 59.25 (neutral) * MACD: Bullish crossover above signal line * Stochastic %K/D: Neutral readings

Volume Analysis: * Volume SMA 20: 1225398.40 (low volume) * On-Balance Volume (OBV): 38863137.39 (positive OBV)

News & Sentiment Analysis Recent Headlines Summary: Positive news headlines, highlighting partnerships and operational highlights Sentiment Assessment: Overall sentiment is POSITIVE Catalyst Identification: * Upcoming earnings release could provide catalyst for further price movement

Market Narrative: Technical signals are strong, but news sentiment is also positive, suggesting a neutral market narrative

Risk & Volatility Assessment Beta Interpretation: Low volatility - stock moves less than market (beta 0.74) Volatility Regime: Historical volatility levels suggest moderate risk Options Market Signals: * IV Rank: Medium (30.9%) * Put/Call Volume Ratio: Neutral sentiment (0.95) * Market Expectation: Options market pricing $9.90 move by expiration

Market Context & Positioning Sector Performance: Relative strength vs sector/market Institutional Activity: Moderate institutional interest, as seen in volume trends and OBV Correlation Analysis: * Correlation with SPY: 0.29 (low correlation) Relative Valuation: Stock is trading within a defined range

Key Levels & Action Items Critical Price Levels: * SMA 20: $161.25 (support) * Upper Bollinger Band: $168.01 (resistance)

Breakout/Breakdown Levels: * SMA 50: $150.26 (breakdown risk) * Lower Bollinger Band: $154.49 (breakdown risk)

Time-Sensitive Catalysts: * Upcoming earnings release could provide catalyst for further price movement

Risk Management: * Stop-loss levels: below SMA 20 or at upper Bollinger Band * Position sizing considerations: moderate position size due to low volatility

Generated 2026-06-26 05:39 UTC
Earnings History
5 of 8 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-01 After-Close 13.73% 0.08% 0.01x Within
2024-10-30 After-Close 5.61% 3.00% 0.53x Within
2025-02-06 After-Close 14.26% 9.17% 0.64x Within
2025-05-05 After-Close 10.70% 8.04% 0.75x Within
2025-07-30 After-Close 8.36% 7.23% 0.86x Within
2025-10-28 After-Close 11.19% 14.80% 1.32x Exceeded
2026-02-11 After-Close 8.32% 10.53% 1.27x Exceeded
2026-05-05 After-Close 8.97% 9.04% 1.01x Exceeded
Options Activity
IV Rank (30D)
13.55
IV Rank (7D)
13.55
Avg IV
44.2%
Straddle (30D)
$9.60
Straddle (7D)
$9.60
P/C Volume
0.47
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.73
Correlation (SPY)
28.8%
R²
0.08
Ann. Volatility
31.7%
SPY Volatility
12.5%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 102,350,000 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

708 filers100,223,501 shares$12.97B value97.92% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 13,385,607 $1.76B 13.60% 13.08% 2026-03-31
2 VANGUARD GROUP INC Custodian 9,700,301 $1.38B 10.61% 9.48% 2025-12-31
3 DODGE & COX 5,461,037 $719.44M 5.55% 5.34% 2026-03-31
4 JPMORGAN CHASE & CO Custodian 5,442,067 $700.50M 5.40% 5.32% 2026-03-31
5 AQR CAPITAL MANAGEMENT LLC Custodian 4,938,967 $650.66M 5.02% 4.83% 2026-03-31
6 STATE STREET CORP 4,354,526 $573.67M 4.42% 4.25% 2026-03-31
7 TWO SIGMA INVESTMENTS, LP 3,060,570 $403.20M 3.11% 2.99% 2026-03-31
8 RENAISSANCE TECHNOLOGIES LLC 2,418,897 $318.67M 2.46% 2.36% 2026-03-31
9 GEODE CAPITAL MANAGEMENT, LLC Custodian 2,136,672 $280.80M 2.16% 2.09% 2026-03-31
10 BNP Paribas Asset Management Holding S.A. 1,493,813 $196.77M 1.52% 1.46% 2026-03-31
11 WELLINGTON MANAGEMENT GROUP LLP Custodian 1,389,539 $183.06M 1.41% 1.36% 2026-03-31
12 MORGAN STANLEY Custodian 1,209,378 $171.53M 1.32% 1.18% 2025-12-31
13 Vestal Point Capital, LP 1,250,000 $164.68M 1.27% 1.22% 2026-03-31
14 MILLENNIUM MANAGEMENT LLC Custodian 1,247,447 $164.34M 1.27% 1.22% 2026-03-31
15 NORTHERN TRUST CORP Custodian 1,242,830 $163.73M 1.26% 1.21% 2026-03-31
16 UBS Group AG Custodian 1,221,036 $160.86M 1.24% 1.19% 2026-03-31
17 RTW INVESTMENTS, LP 1,062,072 $139.92M 1.08% 1.04% 2026-03-31
18 FIRST TRUST ADVISORS LP 959,217 $126.37M 0.97% 0.94% 2026-03-31
19 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 902,788 $118.93M 0.92% 0.88% 2026-03-31
20 IEQ CAPITAL, LLC 765,982 $100.91M 0.78% 0.75% 2026-03-31
21 VICTORY CAPITAL MANAGEMENT INC 731,609 $96.38M 0.74% 0.71% 2026-03-31
22 ARMISTICE CAPITAL, LLC 724,000 $95.38M 0.74% 0.71% 2026-03-31
23 DIMENSIONAL FUND ADVISORS LP Custodian 711,762 $93.75M 0.72% 0.70% 2026-03-31
24 Bank of New York Mellon Corp Custodian 702,492 $92.55M 0.71% 0.69% 2026-03-31
25 BRAIDWELL LP 652,121 $85.91M 0.66% 0.64% 2026-03-31
13 filers$39.94M notional
# Filer Notional Value % of Total Period
1 JANE STREET GROUP, LLC Custodian $10.62M 26.59% 2026-03-31
2 JPMORGAN CHASE & CO Custodian $10.43M 26.11% 2026-03-31
3 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $4.45M 11.15% 2026-03-31
4 Caption Management, LLC $3.95M 9.90% 2026-03-31
5 CITIGROUP INC Custodian $2.37M 5.94% 2026-03-31
6 Twin Tree Management, LP $2.28M 5.71% 2026-03-31
7 CITADEL ADVISORS LLC Custodian $1.82M 4.55% 2026-03-31
8 IMC-Chicago, LLC Custodian $1.61M 4.02% 2026-03-31
9 Walleye Trading LLC $1.05M 2.64% 2026-03-31
10 WOLVERINE TRADING, LLC Custodian $883.70K 2.21% 2025-09-30
11 Jefferies Financial Group Inc. $329.35K 0.82% 2026-03-31
12 SIMPLEX TRADING, LLC Custodian $92.22K 0.23% 2026-03-31
13 Raiffeisen Bank International AG $52.70K 0.13% 2026-03-31
12 filers$69.04M notional
# Filer Notional Value % of Total Period
1 JANE STREET GROUP, LLC Custodian $23.92M 34.65% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $19.15M 27.75% 2026-03-31
3 JPMORGAN CHASE & CO Custodian $10.43M 15.10% 2026-03-31
4 Caption Management, LLC $3.95M 5.72% 2026-03-31
5 CITIGROUP INC Custodian $2.37M 3.43% 2026-03-31
6 CITADEL ADVISORS LLC Custodian $2.16M 3.13% 2026-03-31
7 IMC-Chicago, LLC Custodian $1.98M 2.86% 2026-03-31
8 GOLDMAN SACHS GROUP INC Custodian $1.80M 2.61% 2026-03-31
9 SIG BROKERAGE, LP $1.30M 1.89% 2026-03-31
10 SIMPLEX TRADING, LLC Custodian $1.11M 1.60% 2026-03-31
11 Walleye Trading LLC $487.44K 0.71% 2026-03-31
12 GROUP ONE TRADING LLC Custodian $368.87K 0.53% 2026-03-31
Insider Activity
Latest: 2026-06-09
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-09 Jude Onyia Chief Scientific Officer Gift (G) −2,441 — EDGAR
2026-06-09 STEPHEN A SHERWIN Director Mixed — $114.71 -$2.53M EDGAR
2026-06-08 Leslie V Norwalk Director Sell (S) −1,250 $168.06 -$210.1K EDGAR
2026-06-04 Sanjay Chandru Keswani Chief Medical Officer Mixed +1,479 $154.84 -$268.3K EDGAR
2026-06-04 Julie Cooke Chief Human Resources Officer Mixed −11,972 $126.08 -$3.74M EDGAR
2026-06-02 Ingrid Delaet Chief Regulatory Officer Mixed — $117.87 -$175.7K EDGAR
2026-06-02 Jude Onyia Chief Scientific Officer Mixed — $122.49 -$830.6K EDGAR
2026-05-29 Leslie V Norwalk Director Grant (A) +3,908 RSU — EDGAR
2026-05-29 WILLIAM H RASTETTER Director Grant (A) +2,567 RSU — EDGAR
2026-05-29 GEORGE J MORROW Director Grant (A) +2,567 RSU — EDGAR
2026-05-29 STEPHEN A SHERWIN Director Grant (A) +2,567 RSU — EDGAR
2026-05-29 Shalini Sharp Director Grant (A) +2,567 RSU — EDGAR
2026-05-29 CHRISTINE A POON Director Grant (A) +2,567 RSU — EDGAR
2026-05-29 Johanna Mercier Director Grant (A) +2,567 RSU — EDGAR
2026-05-29 GARY A LYONS Director Grant (A) +3,908 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
35 insiders · @ $168.52
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 BVF INVESTMENTS LLC 10,257,894 $1.73B -$2.39M 3 2010-04-13
2 MARK N LAMPERT 10%+ Owner 8,847,147 $1.49B -$647.3K 2 2011-10-14
3 BVF PARTNERS L P/IL 10%+ Owner 6,658,212 $1.12B -$8.66M 4 2012-02-10
4 BIOTECHNOLOGY VALUE FUND L P 5,905,447 $995.19M $1.80M 3 2009-01-22
5 BIOTECHNOLOGY VALUE FUND II LP 756,600 $127.50M $2.48M 1 2011-10-12
6 KEVIN CHARLES GORMAN Director 756,381 $127.47M -$181.28M 73 2026-05-29
7 Haig P. Bozigian Chief Development Officer 157,651 $26.57M -$53.74M 66 2021-03-29
8 Kyle Gano Chief Executive Officer 156,193 $26.32M -$49.45M 58 2026-02-17
9 Timothy Coughlin Chief Financial Officer 137,961 $23.25M -$12.42M 40 2017-02-08
10 GARY A LYONS Director 122,141 $20.58M -$23.43M 57 2026-05-29
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-06-05
Last 30d: 6 filings · $14.5M notice value  ·  Last 90d: 9 filings · $56.5M notice value · 8 unique filers · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Parsed directly from EDGAR primary-doc XML. Daily refresh; new filings typically appear here the morning after they hit EDGAR.

Top 90-day filers: KEVIN CHARLES GORMAN (1, $38.5M) · JULIE COOKE (1, $5.9M) · STEPHEN SHERWIN (1, $4.2M) · JUDE ONYIA (2, $3.5M) · RICHARD F POPS (1, $2.4M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-06-05 STEPHEN SHERWIN Director 25,000 $4.18M 2026-06-05 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-02 JULIE COOKE Officer 36,937 $5.95M 2026-06-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-01 JUDE ONYIA Officer 11,000 $1.74M 2026-06-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-05-29 INGRID DELAET Officer 2,261 $353.6K 2026-05-29 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-05-27 JUDE ONYIA Officer 11,000 $1.71M 2026-05-27 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-05-26 DAVID WARREN BOYER Officer 3,888 $609.2K 2026-05-26 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-05-19 KEVIN CHARLES GORMAN Director 245,088 $38.53M 2026-05-19 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-05-15 RICHARD F POPS Director 15,000 $2.39M 2026-05-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-05-12 Norwalk Leslie V Director 6,310 $1.03M 2026-05-12 THE CHARLES SCHWAB CORPORATION 10b5-1 EDGAR
2026-01-16 KYLE GANO Officer 36,400 $4.85M 2026-01-16 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
Recent SEC Filings
Latest: 2026-05-28
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-05-28 0000914475-26-000029 EDGAR
2026-05-18 0001193125-26-228013 EDGAR
2026-05-05 0000914475-26-000025 EDGAR
2026-04-06 0001193125-26-142904 EDGAR
2026-02-11 0000914475-26-000006 EDGAR
2025-11-24 0000914475-25-000186 EDGAR
2025-10-28 0000914475-25-000180 EDGAR
2025-07-30 0000914475-25-000157 EDGAR
2025-05-30 0000914475-25-000139 EDGAR
2025-05-22 0000914475-25-000120 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-11 0000914475-26-000007 EDGAR
2025-02-10 0000914475-25-000037 EDGAR
2024-02-09 0000914475-24-000054 EDGAR
2023-02-09 0000914475-23-000011 EDGAR
2022-02-11 0000914475-22-000013 EDGAR
2021-02-05 0000914475-21-000020 EDGAR
2020-02-07 0001564590-20-003773 EDGAR
2019-02-08 0001564590-19-002328 EDGAR
2018-02-13 0001193125-18-042794 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-05-05 0000914475-26-000026 EDGAR
2025-10-28 0000914475-25-000181 EDGAR
2025-07-30 0000914475-25-000158 EDGAR
2025-05-05 0000914475-25-000100 EDGAR
2024-10-30 0000914475-24-000211 EDGAR
2024-08-01 0000914475-24-000181 EDGAR
2024-05-01 0000914475-24-000117 EDGAR
2023-10-31 0000914475-23-000073 EDGAR
2023-08-01 0000914475-23-000057 EDGAR
2023-05-03 0000914475-23-000044 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/E Ratio25.8
P/B Ratio4.8
P/S Ratio5.3
EV/EBITDA19.6
TTM Revenue$3.1B
TTM Net Income$0.7B
TTM EPS$6.49
ROE19.6%